Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

11/12/24 9:55:17 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CYTK alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 CYTOKINETICS INC COMMON STOCK Cusip #23282W605 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #23282W605 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 12,216,482 Item 6: 0 Item 7: 12,415,642 Item 8: 0 Item 9: 12,415,642 Item 11: 10.518% Item 12: HC Cusip #23282W605 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 12,415,642 Item 8: 0 Item 9: 12,415,642 Item 11: 10.518% Item 12: IN Item 1(a). Name of Issuer: CYTOKINETICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 350 OYSTER POINT BOULEVARD South San Francisco, CA 94080 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 23282W605 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 12,415,642 (b) Percent of Class: 10.518% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 12,415,642 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CYTOKINETICS INC. No one other person's interest in the COMMON STOCK of CYTOKINETICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of CYTOKINETICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $CYTK alert in real time by email

Recent Analyst Ratings for

$CYTK

Date	Price Target	Rating	Analyst
11/8/2024	$80.00	Outperform	RBC Capital Mkts
8/13/2024	$85.00 → $60.00	Buy → Neutral	Goldman
1/24/2024	$61.00 → $92.00	Buy → Neutral	UBS
1/5/2024	$60.00 → $90.00	Overweight → Equal-Weight	Morgan Stanley
11/9/2023	$50.00	Buy	Goldman
11/7/2023	$66.00	Buy	B. Riley Securities
8/15/2023	$58.00	Outperform	SVB Securities
2/17/2023	$49.00	Neutral	BofA Securities

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

Chat with this insight

Recent Analyst Ratings for $CYTK

$CYTK Financials

Live finance-specific insights

Cytokinetics Reports Third Quarter 2024 Financial Results

Cytokinetics to Announce Third Quarter Results on November 6, 2024

Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024

$CYTK Market Insights

Live Market Insights

JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $65

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $90 Price Target

Cytokinetics Has Dosed The First Participants In A Phase 1 Study Evaluating The Pharmacokinetics, Safety And Tolerability Of Aficamten In Healthy Japanese And Caucasian Participants

$CYTK SEC Filings

SEC Form 10-Q filed by Cytokinetics Incorporated

Cytokinetics Incorporated filed SEC Form 8-K: Leadership Update

Cytokinetics Incorporated filed SEC Form 8-K: Leadership Update

$CYTK Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$CYTK Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$CYTK Large Ownership Changes

This live feed shows all institutional transactions in real time.

EVP Research & Development Malik Fady Ibraham exercised 5,300 shares at a strike of $7.96 and sold $370,880 worth of shares (6,342 units at $58.48), decreasing direct ownership by 0.91% to 113,878 units (SEC Form 4)

President & CEO Blum Robert I sold $258,150 worth of shares (5,000 units at $51.63) and exercised 5,000 shares at a strike of $6.67 (SEC Form 4)

Director Wierenga Wendall exercised 4,452 shares at a strike of $7.37 and sold $232,617 worth of shares (4,452 units at $52.25) (SEC Form 4)

RBC Capital Mkts initiated coverage on Cytokinetics with a new price target

Cytokinetics downgraded by Goldman with a new price target

Cytokinetics downgraded by UBS with a new price target